Ladenburg Thalmann Financial Services’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$14K	Buy	866 +797	+1,155%	+$12.4K	﹤0.01%	4334
2019 Q3	$0	Buy	69 +34	+97%	+$416	﹤0.01%	5486
2019 Q2	$0	Hold	35	–	–	﹤0.01%	5445
2019 Q1	$1K	Hold	35	–	–	﹤0.01%	5128
2018 Q4	$1K	Hold	35	–	–	﹤0.01%	5107
2018 Q3	$1K	Buy	+35	New	+$952	﹤0.01%	5055
2016 Q3	–	Sell	-12	Closed	–	–	4888
2016 Q2	$0	Buy	+12	New	+$212	﹤0.01%	4857

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Ladenburg Thalmann Financial Services's RVNC Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Revance Therapeutics, Inc. (RVNC) stake by 1,155% in Q4 2019, buying an estimated $12.4K and bringing the position to 866 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #4334.

Ladenburg Thalmann Financial Services first reported a position in RVNC in Q2 2016 and has held it in 7 quarters since. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

Ladenburg Thalmann Financial Services held 866 shares of Revance Therapeutics, Inc. worth $14K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 797 Revance Therapeutics, Inc. shares in Q4 2019, an estimated $12.4K.
Revance Therapeutics, Inc. made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4334 holding.
Ladenburg Thalmann Financial Services first reported a position in Revance Therapeutics, Inc. in Q2 2016 and has held it in 7 quarters since.
134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.